Showing 1801-1810 of 5957 results for "".
- CMS Provides Regulatory Relief on Staffing, Paperwork as COVID-19 Cases Surgehttps://modernod.com/news/cms-provides-regulatory-relief-on-staffing-paperwork-as-covid-19-cases-surge/2477504/The Trump administration released a raft of regulatory changes intended to bolster hospitals including setting up alternative sites of care and methods to rapidly boost healthcare workers, according to a FierceHealthcare
- Santen Announces Initiation of Phase 3 Clinical Program (SPECTRUM) Evaluating Glaucoma Treatment Omidenepag Isopropyl (DE-117)https://modernod.com/news/santen-announces-initiation-of-phase-3-clinical-development-program-spectrum-in-the-united-states-evaluating-omidenepag-isopropyl-de-117-for-the-treatment-of-glaucoma-or-ocular-hypertension/2479772/Santen announced the initiation of the pivotal phase 3 development program (SPECTRUM) in the United States, evaluating the investigational use of omidenepag isopropyl (DE-117), a selective agonist for the prostanoid receptor EP2, for the treatment of glaucoma or o
- The Vision Council Announces Dates for the 2021 Virtual Executive Summit: January 26–28, 2021https://modernod.com/news/the-vision-council-announces-dates-for-the-2021-virtual-executive-summit-january-26-28-2021/2478440/The Vision Council today announces that the
- FDA Grants Notal Vision Home OCT System De Novo Marketing Authorizationhttps://modernod.com/news/fda-grants-notal-vision-home-oct-scanly-de-novo-marketing-authorization/2482282/Notal Vision announced that the FDA has granted De Novo authorization for its patient self-operated Scanly Home OCT device. Designated by the FDA as a breakthrough device for patients suffering from wet age-related macular degeneration (AMD), Scanly Home OCT aims to improve persona
- First Patients Enrolled in 4DMT's Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMDhttps://modernod.com/news/first-patients-enrolled-in-4dmts-phase-3-clinical-trial-evaluating-4d-150-in-wet-amd/2482694/4D Molecular Therapeutics (4DMT) announced that the first patients have been enrolled across multiple sites in the 4FRONT-1 phase 3 clinical trial evaluating 4D-150 for the treatment of wet age-related macular degeneration (AMD). "This is a historic moment for 4DMT as we becom
- Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-first-patients-enrolled-in-phase-1-2a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2478744/Clearside Biomedical announced that the first patients have been enrolled in its phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). Clinical sites, all based in the United States, are activated and curr
- Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbanceshttps://modernod.com/news/ocuphire-pharma-initiates-lynx-1-phase-3-study-investigating-nyxol-in-night-vision-disturbances/2478713/Ocuphire Pharma announced the initiation of patient recruitment and screening in late December for its LYNX-1 phase 3 registration study evaluating the safety and efficacy of Nyxol in night vision disturbances (NVD) at multiple sites in the US. NVD, also known as dim light vision disturban
- Vertex Aims for “Virtual Clinic Visits” to Keep Ongoing Studies on Track Amid COVID-19 Pandemichttps://modernod.com/news/vertex-aims-for-virtual-clinic-visits-to-keep-ongoing-studies-on-track-amid-covid-19-pandemic/2477483/Vertex Pharmaceuticals said that due to the COVID-19 pandemic, the company is working with clinical trial sites to enable “virtual clinic visits” and home delivery of study drugs to ensure that ongoing trials continue as planned with the correct monitoring and procedures in place. How
- Asepticys Files 510k Submission With FDA for TriFlect Disinfection Technologyhttps://modernod.com/news/asepticys-files-510k-submission-with-fda-for-triflect-disinfection-technology/2476450/Asepticys announced the completion of multisite human clinical trials for Asepticys’ novel contact lens care solution containing TriFlect technology. The company has submitted a 510(k) application to the FDA. The clinical trials involved over 320 patients at 12 sites across
- Bausch + Lomb Launches Sightmatters.com to Help People Living With AMDhttps://modernod.com/news/bausch-lomb-launches-sightmatters-com-to-help-people-living-with-amd/2476325/Bausch + Lomb announced the launch of SightMatters.com, a new educational online resource for people living with age-related macular degeneration (AMD). Bausch + Lomb launched the site to coincide with the start of AMD Awareness Month. The new online resource, which was specifically design